ArticleNeonatology2025
Impact of Implementing Nasal High Flow Therapy on Body Growth in Preterm Infants.
Article in Neonatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: The objective of this study was to determine the impact of nasal high flow (nHF) implementation on lung growth at 6 months corrected age (CA) in preterm infants.
methodsThis single-center retrospective cohort study included preterm infants born <30 weeks' gestation and surviving to 6 months CA at the neonatal intensive care unit of the Amsterdam University Medical Centers. In the nCPAP cohort (2009-2012), continuous distending pressure (CDP) was applied solely with nasal continuous positive airway pressure support. In the nHF cohort (2015-2018), nCPAP was used and followed by nHF therapy to deliver CDP. Bodyweight and length at 6 months CA were used as a proxy for lung growth. We also assessed the impact on respiratory management and neonatal morbidity. Multivariate analysis was performed after multiple imputation, using a linear regression adjusting for confounding variables.
resultsOf the 598 eligible infants, 313 infants were included in the nCPAP cohort and 285 infants in the nHF cohort. The analyses showed no differences between the nCPAP and nHF cohort in body weight (7.29 vs. 7.31 kilogram, 95% CI -0.14 to 0.20, p = 0.71) and length (66.6 vs. 66.8 centimeters, 95% CI -0.30 to 0.81, p = 0.26) at 6 months CA. No differences in moderate/severe bronchopulmonary dysplasia (BPD) were reported, but nHF implementation was associated with longer CDP duration, a trend toward more days on supplemental oxygen, and a shift from moderate to severe BPD.
conclusionsImplementation of nHF did not impact body growth, which is associated with lung growth, at 6 months CA in preterm infants born <30 weeks. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.